An interventional study of Pregabalin and Placebo in Neuropathic Pain, sponsored by Pfizer. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-23.
Sponsored by Pfizer · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.
Among the 50 studies testing pregabalin in Neuralgia, this one is the 44th largest by enrollment, is one of 6 that started in 2006, is one of 10 with no phase, and was the 21st registered.
1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.
Browse Neuralgia studies →4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Recruiting first, the newest first:
Moumtzidou Maria Aikaterini · Sites in Greece
Ages 18+ · Women only
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 18–75
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–75
Helsinki University Central Hospital · Sites in Finland
Ages 18–75
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 19 · Phase 4 12
First in 2002; this study’s year is marked. 6 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 52 across 832 interventional studies indexed under Neuralgia.
Median enrollment 109 across the 50 interventional studies. Of the 35 that completed or were terminated, 10 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 50 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 7 studies filed under Neuralgia — fewer than ten, so there is no comparison to draw.
2 of the studies testing pregabalin in Neuralgia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712913Phase 3Brainfarma Industria Química e Farmacêutica S/AExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | 2027-06-01 |
| NCT07880223Moumtzidou Maria AikateriniComparison of Two Postoperative Care Strategies After Breast Surgery | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 50 studies testing pregabalin in Neuralgia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Conventional pain efficacy measures such as Visual Analogue Scores (VAS) are often unable to detect treatment efficacy in small-scale clinical trials. Combining conventional pain efficacy measures with quantitative sensory testing (QST) may provide more sensitive and informative outcome measures in clinical trials.
Methodology to assess reproducibility and sensitivity of quantitative sensory testing
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Pregabalin
Drug: Placebo
Dose titration according to following regimen: 75mg BID for 3 days; 150mg for 4 days; 225mg BID for 4 days; 300mg BID for 17 days. Dose reduced for renally impaired patients
BID dosing for 28 days
Mean Change From Baseline in Dynamic Allodynia Intensity at Visits 3 and 6 and Visits 4 and 7
Five strokes applied with a standardized brush (somedic) across the painful site, 6cm long and at a control site to allow the participants to appreciate any difference. A painful and clearly dysaesthetic (unpleasant) sensation was considered as representing brush allodynia (whereas a "strange" or "tickly" sensation provoked by the brush was not). After each brush stimuli participants were asked to give a pain rating using 11-point numerical rating scale (NRS) where 0=no pain and 10=worst pain imaginable. The average of 5 brush strokes was calculated to obtain the mean score.
Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Mean Change From Baseline in Dynamic Allodynia Area at Visits 3 and 6 and Visits 4 and 7
Dynamic area brush in cm\^2: calculated from 8 measured distances by calculating the area of an octagon. The angle between each pair of lines was 45 degrees at point c. The area of the octagon was found by totaling the areas of the 8 triangles. Octagon with 8 radial lengths from center to the outside. Area = Σ ( ½ length \* perpendicular height); Σ ( ½ ri \* sin(45) r(i+1) ) = Σ ( (ri \* r(i+1) )/2√2)). (where ri, i=1 to 8, were the eight radial lengths)
Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Mean Change From Baseline in Mechanical Pain Sensitivity (Von Frey) at Visits 3 and 6 and Visits 4 and 7
Sensitivity to mechanical pain stimuli was tested using calibrated Von Frey monofilaments. To obtain a stimulus-response-function, seven different Von Frey monofilaments (size 8 to 512 mN, force increased by a factor of two from filament to filament) applied three times each; each stimulus was participant-rated using 11-point NRS where 0=no pain and 10=worst pain imaginable. If a score of 8 or more was reported for a given intensity no stronger stimuli was applied. Von Frey stimulus was applied to the skin for 1 to 2 seconds. The average of 3 ratings was calculated for the mean score.
Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Mean Change From Baseline in Punctate Allodynia Area (Von Frey) at Visits 3 and 6 and Visits 4 and 7
Punctate allodynia area in cm\^2: calculated from 8 measured distances by calculating the area of an octagon. The angle between each pair of lines was 45 degrees at point c. The area of the octagon was found by totaling the areas of the 8 triangles. Octagon with 8 radial lengths from center to the outside. Area = Σ ( ½ length \* perpendicular height); Σ ( ½ ri \* sin(45) r(i+1) ) = Σ ( (ri \* r(i+1) )/2√2)). (where ri, i=1 to 8, were the eight radial lengths)
Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Mean Change From Baseline in Cold Pain Sensitivity at Visits 3 and 6 and Visits 4 and 7
Duration of thermal stimuli was 2 seconds and an intensity that is increased in steps of 5 degrees celsius for cold stimuli (between 5 and 20 degrees celsius). Thermal pain sensitivity was participant-rated using 11-point NRS where 0=no pain and 10=worst pain imaginable. The average of 2 ratings was calculated to get the mean score.
Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Mean Change From Baseline in Heat Pain Sensitivity at Visits 3 and 6 and Visits 4 and 7
Duration of thermal stimuli was 2 seconds and an intensity that is increased in steps of 4 degrees celsius for heat stimuli (between 40 and 50 degrees celsius). Thermal pain sensitivity was participant-rated using 11-point NRS where 0=no pain and 10=worst pain imaginable. The average of 2 ratings was calculated to get the mean score.
Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Mean Change From Baseline in Weekly Pain Score From the Daily Diary at Visits 3 and 6 and Visits 4 and 7
Daily pain diary: participant-rated pain during the past 24 hours rated on an 11 point NRS scale where 0=no pain and 10=worst possible pain. For a given week, the pain response was the average of the 7 daily entries for that week, or average of the available data for that week if fewer than 7 entries were recorded (\>=1 daily pain score for any given week required). The endpoint for each week consisted of the change from baseline in average pain score (follow-up value minus baseline).
Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Mean Change From Baseline in Patient's Global Impression of Change (PGIC) at Visits 3 and 6 and Visits 4 and 7
PGIC: participant-rated assessment measuring change in participant's overall status on a 7-point scale from 1=very much improved to 7=very much worse.
Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Mean Change From Baseline in Test-Day Global Pain Intensity at Visits 3 and 6 and Visits 4 and 7
Global pain: participant-rated pain using the test-day global pain scale, consisting of an 11-point NRS where 0 = no pain and 10 = worst possible pain. Participants described intensity of pain in response to "How intense is your pain today?"
Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Mean Change From Baseline in Neuropathic Pain Symptom Inventory (NPSI) Total Score at Visits 4 and 7
NPSI: 10-item self-administered questionnaire assessing 5 dimensions of pain (burning superficial spontaneous pain, pressing deep spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia). Each item consists of a question about the specific qualities of pain and an 11-point numerical scale range: 0 (absence of pain) to 10 (maximum intensity imaginable), and 2 temporal items related to spontaneous and paroxysmal pain. Maximum total score possible = 100.
Time frame: Week 4 (Visits 4 and 7) of each period
| Milestone | Pregabalin Then Placebo | Placebo Then Pregabalin |
|---|---|---|
| Started | 14 | 17 |
| Received treatment | 14 | 17 |
| Completed | 13 | 16 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Milestone | Pregabalin Then Placebo | Placebo Then Pregabalin |
|---|---|---|
| Started | 13 | 16 |
| Completed | 13 | 14 |
| Not completed | 0 | 2 |
| Withdrew: Protocol violation | 0 | 2 |
| Milestone | Pregabalin Then Placebo | Placebo Then Pregabalin |
|---|---|---|
| Started | 13 | 14 |
| Completed | 11 | 9 |
| Not completed | 2 | 5 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Other | 1 | 2 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Five strokes applied with a standardized brush (somedic) across the painful site, 6cm long and at a control site to allow the participants to appreciate any difference. A painful and clearly dysaesthetic (unpleasant) sensation was considered as representing brush allodynia (whereas a "strange" or "tickly" sensation provoked by the brush was not). After each brush stimuli participants were asked to give a pain rating using 11-point numerical rating scale (NRS) where 0=no pain and 10=worst pain imaginable. The average of 5 brush strokes was calculated to obtain the mean score.
| scores on a scale | Pregabalin | Placebo |
|---|---|---|
| Week 3 (Visits 3 and 6) (n=15,16) | -1.09 ± 1.735 | -1.16 ± 1.730 |
| Week 4 (Visits 4 and 7) (n=18,21) | -1.31 ± 1.924 | -0.67 ± 1.984 |
Dynamic area brush in cm\^2: calculated from 8 measured distances by calculating the area of an octagon. The angle between each pair of lines was 45 degrees at point c. The area of the octagon was found by totaling the areas of the 8 triangles. Octagon with 8 radial lengths from center to the outside. Area = Σ ( ½ length \* perpendicular height); Σ ( ½ ri \* sin(45) r(i+1) ) = Σ ( (ri \* r(i+1) )/2√2)). (where ri, i=1 to 8, were the eight radial lengths)
| cm2 | Pregabalin | Placebo |
|---|---|---|
| Week 3 (Visits 3 and 6) (n=16,17) | -53.441 ± 114.7084 | -49.180 ± 94.3329 |
| Week 4 (Visits 4 and 7) (n=17,20) | -49.808 ± 100.2094 | -18.921 ± 104.3942 |
Sensitivity to mechanical pain stimuli was tested using calibrated Von Frey monofilaments. To obtain a stimulus-response-function, seven different Von Frey monofilaments (size 8 to 512 mN, force increased by a factor of two from filament to filament) applied three times each; each stimulus was participant-rated using 11-point NRS where 0=no pain and 10=worst pain imaginable. If a score of 8 or more was reported for a given intensity no stronger stimuli was applied. Von Frey stimulus was applied to the skin for 1 to 2 seconds. The average of 3 ratings was calculated for the mean score.
| scores on a scale | Pregabalin | Placebo |
|---|---|---|
| Week 3 (Visits 3 and 6) (Size 8, n=15,16) | -0.133 ± 1.7494 | 0.417 ± 2.6063 |
| Week 3 (Visits 3 and 6) (Size 16, n=15,16) | -1.356 ± 2.4800 | 0.208 ± 2.6412 |
| Week 3 (Visits 3 and 6) (Size 32, n=15,16) | -0.200 ± 1.8551 | -0.188 ± 2.1636 |
| Week 3 (Visits 3 and 6) (Size 64, n=15,16) | -1.128 ± 2.0304 | 0.561 ± 2.9543 |
| Week 3 (Visits 3 and 6) (Size 128, n=15,16) | -1.267 ± 1.6868 | -0.097 ± 1.3385 |
| Week 3 (Visits 3 and 6) (Size 256, n=15,16) | -0.773 ± 2.2420 | -0.171 ± 1.4133 |
| Week 3 (Visits 3 and 6) (Size 512, n=15,16) | -1.533 ± 1.7873 | -0.480 ± 1.1183 |
| Week 4 (Visits 4 and 7) (Size 8, n=18,21) | -0.370 ± 1.2674 | -0.429 ± 1.7132 |
| Week 4 (Visits 4 and 7) (Size 16, n=18,21) | -0.611 ± 1.2693 | -0.889 ± 2.2616 |
| Week 4 (Visits 4 and 7) (Size 32, n=18,21) | -0.333 ± 1.4597 | -0.825 ± 2.1386 |
| Week 4 (Visits 4 and 7) (Size 64, n=18,21) | -1.116 ± 1.6152 | -0.462 ± 3.1381 |
| Week 4 (Visits 4 and 7) (Size 128, n=18,21) | -1.315 ± 1.9322 | -0.841 ± 2.2843 |
| Week 4 (Visits 4 and 7) (Size 256, n=18,21) | -1.322 ± 1.8729 | -0.751 ± 2.5072 |
| Week 4 (Visits 4 and 7) (Size 512, n=18,21) | -1.836 ± 1.7249 | -0.420 ± 2.0238 |
Punctate allodynia area in cm\^2: calculated from 8 measured distances by calculating the area of an octagon. The angle between each pair of lines was 45 degrees at point c. The area of the octagon was found by totaling the areas of the 8 triangles. Octagon with 8 radial lengths from center to the outside. Area = Σ ( ½ length \* perpendicular height); Σ ( ½ ri \* sin(45) r(i+1) ) = Σ ( (ri \* r(i+1) )/2√2)). (where ri, i=1 to 8, were the eight radial lengths)
| cm2 | Pregabalin | Placebo |
|---|---|---|
| Week 3 (Visits 3 and 6) (n=16,17) | -75.571 ± 148.8301 | -3.232 ± 125.8041 |
| Week 4 (Visits 4 and 7) (n=17,20) | -75.834 ± 133.9530 | -4.130 ± 129.8261 |
Duration of thermal stimuli was 2 seconds and an intensity that is increased in steps of 5 degrees celsius for cold stimuli (between 5 and 20 degrees celsius). Thermal pain sensitivity was participant-rated using 11-point NRS where 0=no pain and 10=worst pain imaginable. The average of 2 ratings was calculated to get the mean score.
| scores on a scale | Pregabalin | Placebo |
|---|---|---|
| Week 3 (Visits 3 and 6) (5 degrees, n=15,16) | -0.821 ± 1.2039 | -1.402 ± 3.0295 |
| Week 3 (Visits 3 and 6) (10 degrees, n=15,16) | -0.333 ± 1.3318 | -1.313 ± 2.0402 |
| Week 3 (Visits 3 and 6) (15 degrees, n=15,16) | -0.567 ± 2.3442 | 0.125 ± 1.3478 |
| Week 3 (Visits 3 and 6) (20 degrees, n=15,16) | -0.500 ± 1.9365 | 0.031 ± 1.4314 |
| Week 4 (Visits 4 and 7) (5 degrees, n=18,21) | -0.726 ± 1.3375 | -0.703 ± 2.4746 |
| Week 4 (Visits 4 and 7) (10 degrees, n=18,21) | -0.278 ± 1.3086 | -0.810 ± 1.6239 |
| Week 4 (Visits 4 and 7) (15 degrees, n=18,21) | -0.583 ± 1.2632 | 0.095 ± 1.5622 |
| Week 4 (Visits 4 and 7) (20 degrees, n=18,21) | -0.111 ± 1.4507 | -0.333 ± 0.7130 |
Duration of thermal stimuli was 2 seconds and an intensity that is increased in steps of 4 degrees celsius for heat stimuli (between 40 and 50 degrees celsius). Thermal pain sensitivity was participant-rated using 11-point NRS where 0=no pain and 10=worst pain imaginable. The average of 2 ratings was calculated to get the mean score.
| scores on a scale | Pregabalin | Placebo |
|---|---|---|
| Week 3 (Visits 3 and 6) (40 degrees, n=15,16) | -1.100 ± 2.2216 | -0.625 ± 2.3130 |
| Week 3 (Visits 3 and 6) (44 degrees, n=15,16) | 0.400 ± 3.4959 | -0.938 ± 2.8395 |
| Week 3 (Visits 3 and 6) (47 degrees, n=15,16) | -0.908 ± 2.5249 | -0.578 ± 3.3112 |
| Week 3 (Visits 3 and 6) (50 degrees, n=15,16) | -1.385 ± 2.8981 | -0.865 ± 2.1050 |
| Week 4 (Visits 4 and 7) (40 degrees, n=18,21) | -0.639 ± 2.5771 | -0.143 ± 0.9506 |
| Week 4 (Visits 4 and 7) (44 degrees, n=18,21) | -0.444 ± 4.1084 | -0.495 ± 2.9959 |
| Week 4 (Visits 4 and 7) (47 degrees, n=18,21) | -0.337 ± 3.0065 | -0.083 ± 2.7679 |
| Week 4 (Visits 4 and 7) (50 degrees, n=18,21) | -0.566 ± 2.2423 | -0.387 ± 2.6689 |
Daily pain diary: participant-rated pain during the past 24 hours rated on an 11 point NRS scale where 0=no pain and 10=worst possible pain. For a given week, the pain response was the average of the 7 daily entries for that week, or average of the available data for that week if fewer than 7 entries were recorded (\>=1 daily pain score for any given week required). The endpoint for each week consisted of the change from baseline in average pain score (follow-up value minus baseline).
| scores on a scale | Pregabalin | Placebo |
|---|---|---|
| Week 3 (Visits 3 and 6) (n=19,18) | -1.456 ± 1.8287 | -0.484 ± 2.0721 |
| Week 4 (Visits 4 and 7) (n=18,18) | -1.397 ± 1.4823 | -0.769 ± 1.4778 |
PGIC: participant-rated assessment measuring change in participant's overall status on a 7-point scale from 1=very much improved to 7=very much worse.
| scores on a scale | Pregabalin | Placebo |
|---|---|---|
| Week 3 (Visits 3 and 6) (n=15,16) | 3.3 ± 1.87 | 3.4 ± 1.15 |
| Week 4 (Visits 4 and 7) (n=18,21) | 2.4 ± 1.20 | 3.8 ± 1.63 |
Global pain: participant-rated pain using the test-day global pain scale, consisting of an 11-point NRS where 0 = no pain and 10 = worst possible pain. Participants described intensity of pain in response to "How intense is your pain today?"
| scores on a scale | Pregabalin | Placebo |
|---|---|---|
| Week 3 (Visits 3 and 6) (n=7,10) | -1.5 ± 2.39 | -0.4 ± 2.66 |
| Week 4 (Visits 4 and 7) (n=11,11) | -1.6 ± 1.95 | 0.0 ± 2.94 |
NPSI: 10-item self-administered questionnaire assessing 5 dimensions of pain (burning superficial spontaneous pain, pressing deep spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia). Each item consists of a question about the specific qualities of pain and an 11-point numerical scale range: 0 (absence of pain) to 10 (maximum intensity imaginable), and 2 temporal items related to spontaneous and paroxysmal pain. Maximum total score possible = 100.
| scores on a scale | Pregabalin | Placebo |
|---|---|---|
| Mean Change From Baseline in Neuropathic Pain Symptom Inventory (NPSI) Total Score at Visits 4 and 7 | -10.67 ± 21.404 | -7.72 ± 19.384 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 1/28 (3.6%) | 20/28 (71.4%) |
| Placebo | — | 1/30 (3.3%) | 15/30 (50%) |
| Event | Pregabalin | Placebo |
|---|---|---|
| Menopause and related conditionsReproductive system and breast disorders | 1/28 | 1/30 |
| Postmenopausal haemorrhageReproductive system and breast disorders | 1/28 | 1/30 |
| Event | Pregabalin | Placebo |
|---|---|---|
| SomnolenceNervous system disorders | 7/28 | 1/30 |
| FatigueGeneral disorders | 6/28 | 4/30 |
| Dry mouthGastrointestinal disorders | 4/28 | 1/30 |
| DizzinessNervous system disorders | 4/28 | 2/30 |
| VertigoEar and labyrinth disorders | 3/28 | 1/30 |
| Disturbance in attentionNervous system disorders | 3/28 | 1/30 |
| NauseaGastrointestinal disorders | 1/28 | 3/30 |
| Vision blurredEye disorders | 2/28 | 0/30 |
| DiarrhoeaGastrointestinal disorders | 2/28 | 1/30 |
| Tongue coatedGastrointestinal disorders | 2/28 | 0/30 |
| Age, Customized(participants) | All Participants |
|---|---|
| 18 to 44 years | 9 |
| 45 to 64 years | 12 |
| >=65 years | 10 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 18 |
| Male | 13 |
The record gives a start of Dec 2006, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin